Armored cells

Abstract

A modified vertebrate cell comprising a vertebrate cell encased in reversibly interlinked metal-organic framework (MOF) nanoparticles, and methods of making and using the modified cell, are provided.

1 . A modified vertebrate cell comprising a vertebrate cell encased in reversibly interlinked metal-organic framework (MOF) nanoparticles. 
     
     
         2 . The modified cell of  claim 1  which is a mammalian cell. 
     
     
         3 . The modified cell of  claim 2  which is a human cell. 
     
     
         4 . The modified cell of  claim 1  which is a non-adherent cell. 
     
     
         5 . The modified cell of  claim 1  which is a red blood cell. 
     
     
         6 . The modified cell of  claim 1  which is a hematopoietic cell. 
     
     
         7 . (canceled) 
     
     
         8 . The modified cell of  claim 1  wherein the MOF nanoparticles comprise ZIF-8, MIL-100(Fe), UiO-66-NH 2 , magnetic iron oxide (Fe 3 O 4 ) NPs@ZIF-8, or mesoporous silica NP@ZIF-8, or a combination thereof. 
     
     
         9 . The modified cell of  claim 1  wherein the nanoparticles have a diameter of about 100 am to about 500 nm, about 100 nm to about 200 nm or about 400 nm to about 500 nm. 
     
     
         10 - 11 . (canceled) 
     
     
         12 . The modified cell of  claim 1  wherein the nanoparticles further comprise a covalently attached moiety which optionally is a cell targeting moiety, an optically detectable molecule, a diagnostic molecule or a therapeutic molecule. 
     
     
         13 . (canceled) 
     
     
         14 . The modified cell of  claim 1  wherein the mesopores in the nanoparticles further comprise a molecule which is optionally an optically detectable molecule, a diagnostic molecule or a therapeutic molecule. 
     
     
         15 - 20 . (canceled) 
     
     
         21 . A method of making vertebrate cells encased in reversibly interlinked metal-organic framework nanoparticles, comprising:
 providing a population of vertebrate cells, a population of MOF nanoparticles and a ligand; and   adding the MOF nanoparticles and ligand to the cells under conditions that allow for interconnecting the MOF nanoparticles via the ligand.   
     
     
         22 . The method of  claim 21  wherein the MOF nanoparticles have a negative charge ranging from −3.0 to −30 mV in 0.2× PBS. 
     
     
         23 . The method of  claim 21  wherein the ligand comprises tannic acid, epigallocatechin gallate, epicatechin gallate myricetin, quercetin, quercetagetin, eupafolin, luteolin, scutellarein, dicaffeoylquinic, theaflavin, heaflavin-3′-gallate (TF1), theaflavin-3, 3′-digallate (TF2) or a combination thereof. 
     
     
         24 . The method of  claim 21  wherein the MOF nanoparticles are in an acidic isotonic buffer that alters the zeta potential of the MOF nanoparticles. 
     
     
         25 . The method of  claim 24  wherein the buffer ranges from pH 5 to pH 7. 
     
     
         26 . The method of  claim 21  wherein the cells are red blood cells. 
     
     
         27 . The method of  claim 21  wherein the MOF nanoparticles comprise ZIF-8, MIL-100(Fe), UiO-66, UiO-66-NH 2 , magnetic iron oxide (Fe 3 O 4 ) NPs@ZIF-8, or mesoporous silica NP@ZIF-8, or a combination thereof. 
     
     
         28 - 30 . (canceled) 
     
     
         31 . The method of  claim 21  wherein the nanoparticles further comprise a covalently attached moiety. 
     
     
         32 . (canceled) 
     
     
         33 . The method of  claim 21  wherein the mesopores in the nanoparticles further comprise a molecule. 
     
     
         34 - 35 . (canceled) 
     
     
         36 . A method to disrupt linkages in vertebrate cells encased in reversibly interlinked metal-organic framework (MOF) nanoparticles, comprising:
 contacting a population of vertebrate cells encased in reversibly interlinked metal-organic framework nanoparticles with an agent that disrupts the linkages.   
     
     
         37 . (canceled)